Premier Research

IPAM 10MG

IPAM 10MG

$45.00

Ipamorelin Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that acts as a ghrelin receptor agonist. Preclinical studies in cell cultures and animal models indicate that Ipamorelin stimulates growth hormone (GH) release from pituitary somatotrophs with high selectivity, without significant elevation of cortisol, prolactin, or adrenocorticotropic hormone.[1][2] Key Research Areas Selective Growth Hormone…

6 in stock

Category:
Tags: , ,

Ipamorelin

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue that acts as a ghrelin receptor agonist. Preclinical studies in cell cultures and animal models indicate that Ipamorelin stimulates growth hormone (GH) release from pituitary somatotrophs with high selectivity, without significant elevation of cortisol, prolactin, or adrenocorticotropic hormone.[1][2]

Key Research Areas

  • Selective Growth Hormone Secretion – In rodent and porcine models, Ipamorelin has been shown to induce dose-dependent GH pulses with minimal impact on other pituitary hormones, supporting research into pulsatile GH release mechanisms.[3][4]
  • Metabolic & Anabolic Effects – Preclinical investigations demonstrate increased longitudinal bone growth, improved nitrogen retention, and enhanced lipolysis in animal models of growth hormone axis activation.[5][6]
  • Recovery & Tissue Maintenance Pathways – Studies in muscle and connective tissue models suggest Ipamorelin may support protein synthesis and recovery processes through selective GH elevation without broad endocrine disruption.[7][8]

Product Specifications

CAS Number 170851-70-4
Molecular Formula C38H49N9O5
Molar Mass 711.85 g/mol
Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2
Synonyms Ipamorelin Acetate, NNC 26-0161
Purity ≥99% (HPLC)
Form Lyophilized powder
Storage −20°C (long-term), 2–8°C (reconstituted)
Solubility Bacteriostatic water or sterile saline for reconstitution

References

  1. 1. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
  2. 2. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in healthy volunteers. Pharm Res. 1999. PubMed
  3. 3. Andersen PH, et al. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Regul. 1995. PubMed
  4. 4. Hansen BS, et al. Pharmacological characterization of a new highly potent growth hormone secretagogue. Eur J Endocrinol. 1999. PubMed
  5. 5. Veldhuis JD, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. Growth Horm IGF Res. 2010. PubMed
  6. 6. Sigalos JT, et al. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed
  7. 7. Murphy WJ, et al. Growth hormone and the immune system. Endocr Rev. 1996. PubMed
  8. 8. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998. (Related GHS context)
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.

Related products